Introduction
The prevalence of chronic hepatitis C virus (HCV) infection in patients
with cancer ranges from 1.5% to 32% (1). The availability of highly
effective direct-acting antiviral (DAA) drugs, such as
sofosbuvir/velpatasvir, represents a significant progress for patients
with chronic HCV infection. However, the potential for drug–drug
interactions (DDIs) is major with DAA drugs, especially in patients with
chronic conditions such as cancer (2).
Crizotinib is a tyrosine kinase inhibitor (TKI) targeting anaplastic
lymphoma kinase (ALK), ROS1, and mesenchymal–epithelial transition
(MET) prescribed for non-small cell lung cancer (NSCLC) (3). This case
report highlights a pharmacokinetic DDI between crizotinib and
sofosbuvir/velpatasvir associated with cardiac toxicity.